 Patients with progressive fibres in interstitial lung disease, PFILD, experience a variety of symptoms and impairments which affect their quality of life. These include shortness of breath on exertion, fatigue, and cough, as well as physical limitations such as difficulty performing activities of daily living and emotional distress. Existing patient reported outcome measures, PROMs, need further modification and validation before they can be used in clinical trials to measure the effectiveness of treatments for PFILD. This article was authored by Marlies Wiesenbeek, Maria Molina Molina, Olivier Chassany, and others.